Chad K Porter

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1080651/publications.pdf

Version: 2024-02-01

113 papers	3,703 citations	126907 33 h-index	155660 55 g-index
115 all docs	115 docs citations	115 times ranked	3968 citing authors

#	Article	IF	Citations
1	A disease severity scale for the evaluation of vaccine and other preventive or therapeutic interventions for travellersâ€™ diarrhoea. Journal of Travel Medicine, 2022, 29, .	3.0	6
2	A site assessment tool for inpatient controlled human infection models for enteric disease pathogens. Clinical Trials, 2022, 19, 116-118.	1.6	0
3	CHARM: COVID-19 Health Action Response for Marinesâ€“Association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 test. PLoS ONE, 2022, 17, e0266691.	2.5	1
4	Neutralizing Anti-Granulocyte Macrophage-Colony Stimulating Factor Autoantibodies Recognize Post-Translational Glycosylations on Granulocyte Macrophage-Colony Stimulating Factor Years Before Diagnosis and Predict Complicated Crohnâ€™s Disease. Gastroenterology, 2022, 163, 659-670.	1.3	18
5	0013 Psychomotor Vigilance Test Performance Declines Related to Illness Severity, not Sleep. Sleep, 2022, 45, A5-A6.	1.1	0
6	Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine. EBioMedicine, 2021, 66, 103308.	6.1	35
7	Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection. EBioMedicine, 2021, 66, 103310.	6.1	53
8	Viable virus shedding during SARS-CoV-2 reinfection. Lancet Respiratory Medicine,the, 2021, 9, e56-e57.	10.7	11
9	Enterotoxigenic Escherichia coli (ETEC) vaccines: Priority activities to enable product development, licensure, and global access. Vaccine, 2021, 39, 4266-4277.	3.8	60
10	A systematic review and meta-analysis of Penner serotype prevalence of Campylobacter jejuni in low- and middle-income countries. PLoS ONE, 2021, 16, e0251039.	2.5	5
11	Vaccines for Protecting Infants from Bacterial Causes of Diarrheal Disease. Microorganisms, 2021, 9, 1382.	3.6	23
12	SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study. Lancet Respiratory Medicine,the, 2021, 9, 712-720.	10.7	136
13	Shigella -Specific Immune Profiles Induced after Parenteral Immunization or Oral Challenge with Either Shigella flexneri 2a or Shigella sonnei. MSphere, 2021, 6, e0012221.	2.9	12
14	Exploring Changes in the Host Gut Microbiota During a Controlled Human Infection Model for Campylobacter jejuni. Frontiers in Cellular and Infection Microbiology, 2021, 11, 702047.	3.9	6
15	Enteric Pathogens and Reactive Arthritis: Systematic Review and Meta-Analyses of Pathogen-Associated Reactive Arthritis. Foodborne Pathogens and Disease, 2021, 18, 627-639.	1.8	7
16	Safety and immunogenicity of intramuscularly administered CS6 subunit vaccine with a modified heat-labile enterotoxin from enterotoxigenic Escherichia coli. Vaccine, 2021, 39, 5548-5556.	3.8	21
17	The Controlled Human Infection Model for Enterotoxigenic Escherichia coli. Current Topics in Microbiology and Immunology, 2021, , .	1.1	3
18	Shigella-Controlled Human Infection Models: Current and Future Perspectives. Current Topics in Microbiology and Immunology, 2021, , .	1.1	1

#	Article	IF	Citations
19	Chronic Gastrointestinal and Joint-Related Sequelae Associated with Common Foodborne Illnesses: A Scoping Review. Foodborne Pathogens and Disease, 2020, 17, 67-86.	1.8	22
20	Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G. MSphere, 2020, 5, .	2.9	25
21	A first in human clinical trial assessing the safety and immunogenicity of transcutaneously delivered enterotoxigenic Escherichia coli fimbrial tip adhesin with heat-labile enterotoxin with mutation R192G. Vaccine, 2020, 38, 7040-7048.	3.8	19
22	SARS-CoV-2 Transmission among Marine Recruits during Quarantine. New England Journal of Medicine, 2020, 383, 2407-2416.	27.0	94
23	Establishment of a Controlled Human Infection Model with a Lyophilized Strain of Shigella sonnei 53G. MSphere, 2020, 5, .	2.9	13
24	Oral delivery of Hyperimmune bovine serum antibodies against CS6-expressing enterotoxigenicEscherichia colias a prophylactic against diarrhea. Gut Microbes, 2020, 12, 1732852.	9.8	6
25	Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis. Gastroenterology, 2020, 159, 96-104.	1.3	129
26	Cohort profile of a US military population for evaluating pre-disease and disease serological biomarkers in rheumatoid and reactive arthritis: Rationale, organization, design, and baseline characteristics. Contemporary Clinical Trials Communications, 2020, 17, 100522.	1.1	6
27	A grading system for local skin reactions developed for clinical trials of an intradermal and transcutaneous ETEC vaccine. Vaccine, 2020, 38, 3773-3779.	3.8	5
28	Refinement of the CS6-expressing enterotoxigenic Escherichia coli strain B7A human challenge model: A randomized trial. PLoS ONE, 2020, 15, e0239888.	2.5	5
29	632. A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550mg daily or twice-daily) for Chemoprophylaxis Against Travelersâ€™ Diarrhea Among Deployed U.S. and U.K. Military Personnel (PREVENT TD). Open Forum Infectious Diseases, 2020, 7, S376-S376.	0.9	0
30	How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?. Vaccine, 2019, 37, 4778-4783.	3.8	23
31	The way forward for ETEC controlled human infection models (CHIMs). Vaccine, 2019, 37, 4794-4799.	3.8	10
32	Travelersâ€™ diarrhea: update on the incidence, etiology and risk in military and similar populations â€“ 1990-2005 versus 2005â€“2015, does a decade make a difference?. Tropical Diseases, Travel Medicine and Vaccines, 2019, 5, 1.	2.2	75
33	Clinical endpoints for efficacy studies. Vaccine, 2019, 37, 4814-4822.	3.8	10
34	Cohort profile of the PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects (PREDICTS) study: Rationale, organization, design, and baseline characteristics. Contemporary Clinical Trials Communications, 2019, 14, 100345.	1.1	24
35	Hyperimmune Bovine Colostral Anti-CS17 Antibodies Protect Against Enterotoxigenic Escherichia coli Diarrhea in a Randomized, Doubled-Blind, Placebo-Controlled Human Infection Model. Journal of Infectious Diseases, 2019, 220, 505-513.	4.0	15
36	Campylobacter jejuni capsule types in a Peruvian birth cohort and associations with diarrhoeal disease severity. Epidemiology and Infection, 2019, 147, e149.	2.1	2

#	Article	IF	Citations
37	Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies. Clinical Infectious Diseases, 2019, 69, S580-S590.	5.8	24
38	Consensus Report on Shigella Controlled Human Infection Model: Clinical Endpoints. Clinical Infectious Diseases, 2019, 69, S591-S595.	5.8	23
39	Update on Campylobacter vaccine development. Human Vaccines and Immunotherapeutics, 2019, 15, 1389-1400.	3.3	34
40	Acute illness from Campylobacter jejuni may require high doses while infection occurs at low doses. Epidemics, 2018, 24, 1-20.	3.0	41
41	Rifaximin Fails to Prevent Campylobacteriosis in the Human Challenge Model: A Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Infectious Diseases, 2018, 66, 1435-1441.	5.8	13
42	Campylobacter jejuni transcriptional and genetic adaptation during human infection. Nature Microbiology, 2018, 3, 494-502.	13.3	78
43	1104. Deployment-Associated Infectious Gastroenteritis and Associations With Irritable Bowel Syndrome, Post-Traumatic Stress Disorder, and Combat Stress: A Retrospective Cohort Study Among Deployed United States Military Personnel. Open Forum Infectious Diseases, 2018, 5, S331-S331.	0.9	0
44	Stand-by antibiotics for travellersâ€˜ diarrhoea: risks, benefits and research needs. Journal of Travel Medicine, 2018, 25, .	3.0	5
45	Post-Infectious Functional Gastrointestinal Disorders Among Populations Living in Areas of High Enteric Infection Risk: Adding Some Clarity or Further Muddying the Waters. American Journal of Gastroenterology, 2018, 113, 1287-1289.	0.4	0
46	The Risk of Chronic Gastrointestinal Disorders Following Acute Infection with Intestinal Parasites. Frontiers in Microbiology, 2018, 9, 17.	3.5	8
47	Enterotoxigenic E. coli virulence gene regulation in human infections. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8968-E8976.	7.1	55
48	Enterotoxigenic Escherichia coliâ€“blood group A interactions intensify diarrheal severity. Journal of Clinical Investigation, 2018, 128, 3298-3311.	8.2	45
49	Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity score. PLoS ONE, 2018, 13, e0194325.	2.5	19
50	Montezumaâ€™s revenge - the sequel: The one-hundred year anniversary of the first description of â€œpost-infectiousâ€•irritable bowel syndrome. World Journal of Gastroenterology, 2018, 24, 5076-5080.	3.3	4
51	Epidemiology of Campylobacter Infections among Children in Egypt. American Journal of Tropical Medicine and Hygiene, 2018, 98, 581-585.	1.4	33
52	Epidemiology of inflammatory bowel disease among participants of the Millennium Cohort: incidence, deploymentâ€•related risk factors, and antecedent episodes of infectious gastroenteritis. Alimentary Pharmacology and Therapeutics, 2017, 45, 1115-1127.	3.7	35
53	Developing and utilizing controlled human models of infection. Vaccine, 2017, 35, 6813-6818.	3.8	20
54	Editorial: the Millennium study cohortâ€•evaluating environmental determinates of <scp>IBD</scp> in the 21st Century. Authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 46, 64-65.	3.7	0

#	Article	IF	Citations
55	Vaccination of active component US military personnel against Salmonella Typhi. Vaccine, 2017, 35, 1742-1748.	3.8	4
56	Anti-Microbial Antibodies and Inflammatory Markers are Present in the Serum of Patients with IBD Years Before Diagnosis and can Predict Disease. Gastroenterology, 2017, 152, S605.	1.3	1
57	Prophylactic Efficacy of Hyperimmune Bovine Colostral Antiadhesin Antibodies Against Enterotoxigenic Escherichia coli Diarrhea: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial. Journal of Infectious Diseases, 2017, 216, 7-13.	4.0	53
58	Review: chronic and persistent diarrhea with a focus in the returning traveler. Tropical Diseases, Travel Medicine and Vaccines, 2017, 3, 9.	2.2	22
59	Travelers' Diarrhea: An Update on the Incidence, Etiology, and Risk in Military Deployments and Similar Travel Populations. Military Medicine, 2017, 182, 4-10.	0.8	67
60	Trial Evaluating Ambulatory Therapy of Travelersâ€™ Diarrhea (TrEAT TD) Study: A Randomized Controlled Trial Comparing 3 Single-Dose Antibiotic Regimens With Loperamide. Clinical Infectious Diseases, 2017, 65, 2008-2017.	5.8	49
61	Incidence of Norovirus-Associated Medical Encounters among Active Duty United States Military Personnel and Their Dependents. PLoS ONE, 2016, 11, e0148505.	2.5	13
62	The Epidemiology of Irritable Bowel Syndrome in the US Military: Findings from the Millennium Cohort Study. American Journal of Gastroenterology, 2016, 111, 93-104.	0.4	43
63	Serologic microbial associated markers can predict Crohn's disease behaviour years before disease diagnosis. Alimentary Pharmacology and Therapeutics, 2016, 43, 1300-1310.	3.7	105
64	Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study. Vaccine Journal, 2016, 23, 908-917.	3.1	120
65	Chronic Health Consequences of Acute Enteric Infections in the Developed World. American Journal of Gastroenterology Supplements (Print), 2016, 3, 12-24.	0.7	11
66	Giardia lamblia infection increases risk of chronic gastrointestinal disorders. Tropical Diseases, Travel Medicine and Vaccines, 2016, 2, 17.	2.2	14
67	Incidence and risk factors for disease and non-battle injury aboard the hospital ship USNS COMFORT during a Humanitarian Assistance and Disaster Response Mission, Continuing Promise 2011. Tropical Diseases, Travel Medicine and Vaccines, 2016, 2, 7.	2.2	9
68	An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coli. PLoS ONE, 2016, 11, e0149358.	2.5	29
69	Postinfectious Chronic Health Consequences of Acute Enteric Infections. , 2016, , 389-399.		0
70	Immunological Biomarkers in Postinfectious Irritable Bowel Syndrome. Journal of Travel Medicine, 2015, 22, 242-250.	3.0	32
71	Perceived risk of watery diarrhea and dysentery and intended compliance with chemoprophylaxis among a deployed military population. Tropical Diseases, Travel Medicine and Vaccines, 2015, 1, 7.	2.2	2
72	Typhoid fever cases in the U.S. military. BMC Infectious Diseases, 2015, 15, 424.	2.9	4

#	Article	IF	Citations
73	Establishment of Health Utility Indices for Post-Infectious Functional Gastrointestinal Disorders in Active Duty Us Military. Journal of Travel Medicine, 2015, 22, 237-241.	3.0	3
74	Increased Risk of Functional Gastrointestinal Sequelae After Clostridium difficile Infection Among Active Duty United StatesÂMilitary Personnel (1998â€“2010). Gastroenterology, 2015, 149, 1408-1414.	1.3	29
75	Infectious Gastroenteritis as a Risk Factor for Tropical Sprue and Malabsorption: A Caseâ€“Control Study. Digestive Diseases and Sciences, 2015, 60, 3379-3385.	2.3	11
76	Relative cost-effectiveness of a norovirus vaccine in the deployed military setting compared to a vaccine against Campylobacter sp., ETEC, and Shigella sp.. Vaccine, 2014, 32, 5156-5162.	3.8	15
77	Pathogen-specific risk of chronic gastrointestinal disorders following bacterial causes of foodborne illness. BMC Gastroenterology, 2013, 13, 46.	2.0	57
78	Acute Gastroenteritis and the Risk of Functional Dyspepsia: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2013, 108, 1558-1563.	0.4	39
79	Pathogen-specific Risk of Reactive Arthritis from Bacterial Causes of Foodborne Illness. Journal of Rheumatology, 2013, 40, 712-714.	2.0	22
80	Willingness to receive a hypothetical avian influenza vaccine among US military personnel in mid-deployment. Human Vaccines and Immunotherapeutics, 2013, 9, 2613-2617.	3.3	5
81	Lack of Homologous Protection Against Campylobacter jejuni CG8421 in a Human Challenge Model. Clinical Infectious Diseases, 2013, 57, 1106-1113.	5.8	33
82	Quantifying the Incidence and Burden of Postinfectious Enteric Sequelae. Military Medicine, 2013, 178, 452-469.	0.8	21
83	TheShigellahuman challenge model. Epidemiology and Infection, 2013, 141, 223-232.	2.1	34
84	The Polysaccharide Capsule of Campylobacter jejuni Modulates the Host Immune Response. Infection and Immunity, 2013, 81, 665-672.	2.2	70
85	Postinfectious functional gastrointestinal disorders: a focus on epidemiology and research agendas. Gastroenterology and Hepatology, 2013, 9, 145-57.	0.1	5
86	Detection bias and the association between inflammatory bowel disease andSalmonellaandCampylobacterinfection. Gut, 2012, 61, 635.1-635.	12.1	18
87	Postinfectious Gastrointestinal Disorders Following Norovirus Outbreaks. Clinical Infectious Diseases, 2012, 55, 915-922.	5.8	64
88	The Chronic Gastrointestinal Consequences Associated With Campylobacter. Current Gastroenterology Reports, 2012, 14, 395-405.	2.5	52
89	Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome. BMC Gastroenterology, 2012, 12, 55.	2.0	59
90	The Incidence and Risk of Celiac Disease in a Healthy US Adult Population. American Journal of Gastroenterology, 2012, 107, 1248-1255.	0.4	90

#	Article	IF	Citations
91	Management of Service Members Presenting With Persistent and Chronic Diarrhea, During or Upon Returning From Deployment. Military Medicine, 2012, 177, 627-634.	0.8	7
92	A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC). Vaccine, 2011, 29, 5869-5885.	3.8	74
93	A systematic review of ETEC epidemiology focusing on colonization factor and toxin expression. Vaccine, 2011, 29, 6167-6178.	3.8	229
94	Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine. Vaccine, 2011, 29, 7009-7019.	3.8	72
95	Risk of Functional Gastrointestinal Disorders in U.S. Military Following Self-Reported Diarrhea and Vomiting During Deployment. Digestive Diseases and Sciences, 2011, 56, 3262-3269.	2.3	48
96	Volunteer Challenge With Enterotoxigenic Escherichia coli That Express Intestinal Colonization Factor Fimbriae CS17 and CS19. Journal of Infectious Diseases, 2011, 204, 60-64.	4.0	20
97	The Incidence and Gastrointestinal Infectious Risk of Functional Gastrointestinal Disorders in a Healthy US Adult Population. American Journal of Gastroenterology, 2011, 106, 130-138.	0.4	94
98	Pathogen-specific Risk of Functional Gastrointestinal Disorders, Gastroesophageal Reflux Disease and Celiac Disease Following Acute Enteric Infection. American Journal of Gastroenterology, 2011, 106, S512.	0.4	1
99	The epidemiology of infectious gastroenteritis related reactive arthritis in U.S. military personnel: a case-control study. BMC Infectious Diseases, 2010, 10, 266.	2.9	24
100	Recrudescent Campylobacter jejuni Infection in an Immunocompetent Adult following Experimental Infection with a Well-Characterized Organism. Vaccine Journal, 2010, 17, 80-86.	3.1	29
101	Caught in the Act: In Vivo Development of Macrolide Resistance to Campylobacter jejuni Infection. Journal of Clinical Microbiology, 2010, 48, 3012-3015.	3.9	16
102	The epidemiology of travelers' diarrhea in Incirlik, Turkey: a region with a predominance of heat-stabile toxin producing enterotoxigenic Escherichia coli. Diagnostic Microbiology and Infectious Disease, 2010, 66, 241-247.	1.8	30
103	Campylobacter jejuniStrain CG8421: A Refined Model for the Study of Campylobacteriosis and Evaluation ofCampylobacterVaccines in Human Subjects. Clinical Infectious Diseases, 2009, 49, 1512-1519.	5.8	46
104	Capsule Polysaccharide Conjugate Vaccine against Diarrheal Disease Caused by Campylobacter jejuni. Infection and Immunity, 2009, 77, 1128-1136.	2.2	90
105	Cross-sectional survey of anthrax vaccine coverage and KAP among deployed US military. Hum Vaccin, 2009, 5, 765-769.	2.4	8
106	Infectious Gastroenteritis and Risk of Developing Inflammatory Bowel Disease. Gastroenterology, 2008, 135, 781-786.	1.3	178
107	Characterization of Two Campylobacter jejuni Strains for Use in Volunteer Experimental-Infection Studies. Infection and Immunity, 2008, 76, 5655-5667.	2.2	43
108	Case Series Study of Traveler's Diarrhea in U.S. Military Personnel at Incirlik Air Base, Turkey. Vaccine Journal, 2008, 15, 1884-1887.	3.1	10

#	Article	IF	Citations
109	Randomized Clinical Trial Assessing the Safety and Immunogenicity of Oral Microencapsulated Enterotoxigenic Escherichia coli Surface Antigen 6 with or without Heat-Labile Enterotoxin with Mutation R192G. Vaccine Journal, 2008, 15, 1222-1228.	3.1	27
110	Attitudes towards vaccines and infectious disease risk among U.S. troops. Hum Vaccin, 2008, 4, 298-304.	2.4	4
111	The New World primate, Aotus nancymae, as a model for examining the immunogenicity of a prototype enterotoxigenic Escherichia coli subunit vaccine. Vaccine, 2006, 24, 3786-3792.	3.8	17
112	New World Monkey Aotus nancymae as a Model for Campylobacter jejuni Infection and Immunity. Infection and Immunity, 2006, 74, 790-793.	2.2	36
113	The Effect of Trihalomethane and Haloacetic Acid Exposure on Fetal Growth in a Maryland County. American Journal of Epidemiology, 2005, 162, 334-344.	3.4	59